7780 — Daiken Biomedical Co Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeMid CapNeutral

Annual income statement for Daiken Biomedical Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	—	IFRS
Status:	Final	Final	Final	Final
Revenue
Total Revenue	885	1,190	1,362	1,895
Cost of Revenue
Gross Profit	613	814	856	1,206
Selling / General / Administrative Expenses
Research And Development
Total Operating Expenses	773	986	1,213	1,607
Operating Profit	112	204	149	288
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	110	195	140	417
Provision for Income Taxes
Net Income After Taxes	90.2	160	107	338
Net Income Before Extraordinary Items
Net Income	90.2	160	107	338
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	90.2	160	107	338
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.15	0.267	0.178	0.506
Dividends per Share